Selected article for: "RBD protein and S1 RBD protein"
Author: Guo, Xueyang; Kazanova, Alexandra; Thurmond, Stephanie; Saragovi, H. Uri; Rudd, Christopher E.
Title: Effective chimeric antigen receptor T-cells (CAR-Ts) against SARS-CoV-2
  • Cord-id: stnzcc67
  • Document date: 2021_10_16
    • ID: stnzcc67
    Snippet: Current therapies to treat coronavirus disease 2019 (COVID-19) involve vaccines against the spike (S) protein S1 of SARS-CoV-2. Here, we outline an alternative approach involving chimeric antigen receptors (CARs) in T-cells (CAR-Ts). CAR-T recognition of the SARS-CoV-2 (RBD) peptide induced ribosomal protein S6 phosphorylation, the increased expression of activation antigen, CD69 and effectors, interferon-γ, granzyme B, perforin and Fas-ligand on overlapping subsets of CAR-Ts. CAR-Ts further sh
    Document: Current therapies to treat coronavirus disease 2019 (COVID-19) involve vaccines against the spike (S) protein S1 of SARS-CoV-2. Here, we outline an alternative approach involving chimeric antigen receptors (CARs) in T-cells (CAR-Ts). CAR-T recognition of the SARS-CoV-2 (RBD) peptide induced ribosomal protein S6 phosphorylation, the increased expression of activation antigen, CD69 and effectors, interferon-γ, granzyme B, perforin and Fas-ligand on overlapping subsets of CAR-Ts. CAR-Ts further showed potent in vitro killing of target cells loaded with RBD, S1 peptide or expressing the S1 protein. The efficacy of killing varied with different sized hinge regions, while time-lapse microscopy showed CAR-T cluster formation around RBD expressing targets. Cytolysis of targets was mediated primarily by the GZMB/perforin pathway. Lastly, we showed in vivo killing of S1-expressing cells by our SARS-CoV-2 CAR-T cells in mice. The successful generation of SARS-CoV-2 CAR-Ts represents a living vaccine approach for the treatment of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • absence presence and activate receptor: 1, 2
    • absence presence and active area: 1
    • absence presence and acute lymphoblastic leukemia: 1
    • absence presence and acute severe: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70
    • absence presence and adaptive immune system: 1
    • absence presence and additional information: 1, 2, 3
    • absence presence and additional washing: 1
    • absence presence and adoptive transfer: 1, 2
    • absence presence and long term efficacy: 1, 2
    • absence presence and long term immunity: 1, 2, 3, 4
    • absence presence and low increase: 1, 2
    • absence presence and lymphoblastic leukemia: 1, 2
    • academic medical center and acute severe: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43
    • academic medical center and additional information: 1
    • activate receptor and acute severe: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • activate receptor and adaptive immune system: 1
    • activate receptor and long term immunity: 1
    • activation marker and acute severe: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12